Abeona Therapeutics delivered its first meaningful product-revenue print in Q1 FY2026 - $8.7 million of net ZEVASKYN sales for the quarter ended March 31, 2026, versus zero in the year-ago quarter, a load-bearing inflection for a company that has burned cash since inception. The cost side tells the harder story: selling, general and administrative expense roughly doubled to $19.5 million from $9.8 million as the commercial build-out hit its stride, and the GAAP net loss widened to $17.1 million from $12.0 million, even though the warrant-liability fair-value swing contributed a $5.4 million non-cash gain. We see Q1 FY2026 as the first quarter in which the equity trades as a revenue story rather than a research-and-development option, with three live numbers anchoring the rerating: the cash runway of $168.3 million against a quarterly burn that accelerated to $19.8 million, the six qualified treatment centers now activated versus four at year-end, and the ABO-701 pre-Investigational New Drug meeting on June 3, 2026 that management characterized as constructive with an IND target still pinned to 2027.
The falsifiable clock is the Q2 FY2026 print in early August 2026 plus the next two quarters of qualified treatment center activation data; on the current $19.8 million quarterly burn the $168.3 million of cash resources funds roughly 8.5 quarters of operations, which is the working runway estimate management used in its going-concern assessment that concluded capital was sufficient for at least the next twelve months.